Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lexaria Bioscience Corp. Director's Dealing 2014

Jan 17, 2014

34983_dirs_2014-01-17_c6ec8148-3719-4fe3-98ca-0216b0babb96.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: LEXARIA CORP. (LXRP)
CIK: 0001348362
Period of Report: 2008-07-30

Reporting Person: BUNKA CHRISTOPHER (Director, Chairman, President & CEO, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2008-07-29 Common Shares P 12000 $0.35 Acquired 2086950 Indirect
2008-07-30 Common Shares P 9500 $0.35 Acquired 2096450 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Shares 800000 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Options $0.8 2011-04-26 Common Shares (400000) 400000 Direct
Warrants $0.6 2009-11-09 Common Shares (1166800) 1166800 Indirect

Footnotes

F1: Private Holding Company, C.A.B. Financial Services Ltd., is wholly owned by C. Bunka.

F2: This total was incorrectly understated by 1,000 shares on original filing, resulting in subsequent filing errors in total holdings of same amount, until 4 to 1 conversion at which time, total Indirect holdings were then understated by 250 shares. The correct holdings will be reflected on this amendment and again on January 17, 2014 Form 4A and in all future filings.

F3: This total includes the 800,000 common shares owned Directly.

F4: On June 19, 2007, the exercise price was reduced from $1.30.